Yongliang Niu
YOU?
Author Swipe
View article: Distinct molecular subtypes of <i> KRAS <sup>G12C</sup> </i> ‐mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies
Distinct molecular subtypes of <i> KRAS <sup>G12C</sup> </i> ‐mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies Open
Background KRAS G12C is the most common KRAS mutation in lung adenocarcinoma (LUAD), yet clinical responses to KRAS G12C ‐selective inhibitors (G12Ci) and immunotherapy remain variable. Methods Transcriptomic analysis of KRAS G12C ‐mutant …
View article: Transitional CXCL14<sup>+</sup> cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
Transitional CXCL14<sup>+</sup> cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma Open
Background The heterogeneity of cancer‐associated fibroblasts (CAFs) has become a crucial focus in understanding cancer biology and treatment response, revealing distinct subpopulations with specific roles in tumor pathobiology. CAFs have …
View article: Predicting non-small cell lung cancer lymph node metastasis: integrating ctDNA mutation/methylation profiling with positron emission tomography-computed tomography (PET-CT) scan: protocol for a prospective clinical trial (LUNon-invasive Study)
Predicting non-small cell lung cancer lymph node metastasis: integrating ctDNA mutation/methylation profiling with positron emission tomography-computed tomography (PET-CT) scan: protocol for a prospective clinical trial (LUNon-invasive Study) Open
This study is registered on www.clinicaltrials.gov (NCT06358222).
View article: Minimally invasive surgery role in central squamous lung cancer after neoadjuvant chemoimmunotherapy
Minimally invasive surgery role in central squamous lung cancer after neoadjuvant chemoimmunotherapy Open
This study contributes valuable real-world evidence demonstrating the feasibility and safety of utilizing VATS in the management of patients with centrally located and locally advanced SqCLC following neoadjuvant CIT. However, careful cons…
View article: Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery
Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery Open
The findings from this study indicate that the introduction of third-generation EGFR-TKI Osimertinib did not yield enhanced survival benefits when compared to the first-generation drug in patients with stage IIIA completely resected NSCLC …